North America Cell Therapy Instruments Market Analysis, Size, and Share by 2027

The North America cell therapy instruments market was valued at US$ 5,546.84 million in 2019 and is projected to reach US$ 14,806.33 million by 2027; it is expected to grow at a CAGR of 13.4% during the forecast period.

The rise in cell therapy transplantation's, growing numbers of research and development activities and rising investments for building cell and gene therapy manufacturing plants will drive the growth of the North America cell therapy instruments market during the forecast period. However, the high cost of low success rate and cell-based research are expected to restrain North America Cell Therapy Instruments market growth during the forecast period.

Cell therapy is the therapy involving administration of somatic cell preparations by injecting or grafting into the patient’s body for the treatment of diseases or traumatic damages. Various instruments are used to carry out cell therapy to cure diabetes, neurological disorders, related injuries, some types of cancer, bones and joints and genetic disorders.

The increasing research and development in cell therapy have led to extraordinary therapeutic developments in cell therapy instruments to improve immune system and efficiently treat genetic disorders. Various market players provide several consumables such as reagents kits and enzymes and many companies offer instruments, equipment, and software to conduct a wide range of cell therapy processes.

The use of equipment is important for the production of cell therapies such as NSC, PSC, MSC, T cells and HSC, . These cell therapy products are derived from animals or human cells and thus require safe conditions from contamination. Thus, the instruments used for cell therapies helps in preventing contamination and allows scaling up the transplantation. For instance, companies such as Hitachi Chemical Advanced Therapeutics Solutions, Corning Incorporated, Thermo Fisher Scientific Inc., Miltenyi Biotec, LLC, Invetech and Cytiva (General Electric Company) have introduced various equipment and consumables for the cell therapy.

Across North America, various healthcare research centers were working only for research on COVID 19 therapeutics. Additionally, during the initial phase of COVID-19 crisis, due to lockdown and supply chain disruptions the demand for cell therapy instruments was disrupted owing to change in customer behaviors. However, in long run cell therapy instruments market will have significant growth prospects. For instance, lack of definitive therapy offers significant opportunities for cell therapy instrumentation market as US FDA has recently approved use of plasma therapy for critically ill COVID 19 patients.

North America Cell Therapy Instruments Market Revenue and Forecast to 2027 (US$ Mn)

North America Cell Therapy Instruments Market

By Product

• Consumables
• Equipment
  • Single-Use Equipment
  • Cell Processing Equipment
  • Other Equipment
• Systems and Software

By Cell Type

• Human Cells
  • Differentiated Cells
  • Stem Cells
• Animal Cells

By Process

• Cell Processing
• Process Monitoring and Quality Control
• Cell Preservation, Distribution, and Handling

By End User

• Research Institutes
• Life Science Research Companies
• Other End Users

By Geography

• US
• Canada
• Mexico

List of Companies

• STEMCELL Technologies Inc.
• Miltenyi Biotec
• General Electric Company
• THERMO FISHER SCIENTIFIC INC.
• MERCK KGaA

North America Cell Therapy Instruments Report Scope